GlaxoSmithKline Inc
Connections
Quotes
The new policy will adversely impact GlaxoSmithKline and Sanofi Aventis the most. Bottom lines of domestic drugmakers such as Cipla and Cadila would also take a hit. Least impacted will be companies such as Sun Pharma and Lupin
Our Government continues to work with industry partners such as GlaxoSmithKline Inc., to ensure that Canadians have rapid, priority access to pandemic vaccine in the event of an influenza pandemic.
Scotland continues to attract major investments from some of the world's leading life sciences companies including GlaxoSmithKline and LifeScan, further strengthening Scotland's position as a key cluster for life sciences innovationMore quotes »
Newsday's coverage
-
UK alleges GSK paid off competitors to delay drugs
-- Britain's competition watchdog has accused GlaxoSmithKline of paying off competitors to delay launches of their own versions of GSK's best-selling antidepressant, Seroxat.The Office of Fair Trading alleges GlaxoSmithKline concluded agreements which infringed Read more »
Around the web
-
From Novel Research to Innovative Medicines: GlaxoSmithKline Launches Discovery Fast Track Competition for Academic Researchers
Research Proposals for Chance at Collaborative Partnership Focused on Drug Discovery PHILADELPHIA--(BUSINESS WIRE)-- GlaxoSmithKline plc (GSK) today announced the launch of Discovery Fast Track, a competition designed to accelerate the translation of academic 5/20/13 from Motley Fool Read more »
-
Royalty Pharma raises Elan bid
overpaid" last week when it agreed to pay $1 billion for buy 21% of the royalties that US company Theravance receives from GlaxoSmithKline. Royalty said its takeover offer "represents 100% liquidity for Elan stockholders today, which Royalty Pharma believes 2:47 AM from RTE Interactive Read more »
-
Royalty ups bid as Elan unveils acquisitions
A week after announcing a $1 billion deal giving it access to royalties from Theravance's four respiratory drugs partnered with GlaxoSmithKline, Elan is paying 263.5 million euros in cash and shares (and possibly another 270 million euros) to acquire Austria's 2:39 AM from PharmaTimes Read more »
-
In Depth: Impact Awards
Foundation are accepting applications for their Impact Awards and Mary Linda Andrews, director of community partnerships, GlaxoSmithKline and Chris Budnick, vice president of programs, the Healing Place of Wake County are here to explain more details. 5/20/13 from News 14 Charlotte Read more »
-
GlaxoSmithKline, Ranbaxy among hardest hit in Indian price cuts
by another round of pharma dealmaking. Those price controls, which affect 348 drugs designated as "essential medicines," will hit GlaxoSmithKline ($GSK) hardest among Big Pharma. Domestic drugmakers Cadila Healthcare and Cipla--plus Ranbaxy Laboratories, majority-owned 5/20/13 from FiercePharma Read more »
